{"id":"metoclopramide-granisetron-or-ondansetron","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Constipation"},{"rate":"3-8","effect":"Diarrhea"},{"rate":"3-7","effect":"Fatigue"},{"rate":"2-5","effect":"Dizziness"},{"rate":"0.1-0.5","effect":"Tardive dyskinesia (metoclopramide, with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL1200940","moleculeType":"Small molecule","molecularWeight":"354.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metoclopramide acts as a dopamine antagonist and acetylcholinesterase inhibitor to promote gastric emptying and reduce nausea at the central and peripheral levels. Granisetron and ondansetron selectively block 5-hydroxytryptamine (serotonin) at 5-HT3 receptors, preventing emetic signals from reaching the vomiting center in the brain. These agents are often used in combination or individually to manage chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).","oneSentence":"This is a combination of three distinct antiemetic agents with different mechanisms: metoclopramide blocks dopamine receptors and enhances acetylcholine effects to increase gastric motility, while granisetron and ondansetron are 5-HT3 receptor antagonists that block serotonin signaling in the chemoreceptor trigger zone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:52.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Postoperative nausea and vomiting (PONV)"},{"name":"Gastroparesis (metoclopramide)"},{"name":"Migraine-associated nausea (metoclopramide)"}]},"trialDetails":[{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT01298193","phase":"PHASE4","title":"Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2011-05","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT05087615","phase":"PHASE3","title":"Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2021-03-01","conditions":"Bariatric Surgery Candidate, Perioperative Complication, Nausea","enrollment":130},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT02441894","phase":"PHASE4","title":"Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Prostate Cancer","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5487,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Metoclopramide, Granisetron, or Ondansetron","genericName":"Metoclopramide, Granisetron, or Ondansetron","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three distinct antiemetic agents with different mechanisms: metoclopramide blocks dopamine receptors and enhances acetylcholine effects to increase gastric motility, while granisetron and ondansetron are 5-HT3 receptor antagonists that block serotonin signaling in the chemoreceptor trigger zone. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Gastroparesis (metoclopramide).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}